Laekna scores $61m Series D

Laekna Therapeutics, a developer of next generation medicines to treat cancer and liver diseases, has raised $61 million in Series D financing.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this